

JUN 10 1999

K990871

**510(K) SUMMARY FOR LIFESLEEP SYSTEMS, INC.'S  
PILLOWPOSITIVE**

**Submitter's Name, Address, Telephone Number, and Contact Person**

LifeSleep Systems, Inc.  
400 Oyster Point Boulevard  
Suite 112  
South San Francisco, California 94080

Contact: Anthony A. DiTonno  
President & Chief Executive Officer  
LifeSleep Systems, Inc.  
Phone: (650) 616-9933 / (650) 616-1005  
Facsimile: (650) 616-9930

**Date Prepared**

March 16, 1999

**Name of the Device**

LifeSleep PillowPositive Cervical Pillow

**Common or Usual Name**

Cervical Pillow

**Classification Name**

Truncal Orthosis

**Product Code**

IQK

**Predicate Devices**

LifeSleep Systems's Pillow  
Positive Cervical Pillow

#### **(4) Ortho-Rest Company's A-Just Right Pillow**

##### **Intended Use**

PillowPositive Cervical Pillow ("PillowPositive") is intended for the reduction of symptoms (apnea/hypopnea) associated with mild obstructive sleep apnea by maintaining an open upper airway during sleep.

##### **Principles of Operation**

The PillowPositive places and holds the head and neck in a position that is similar to that used in cardiopulmonary resuscitation, the upper airway remains open, thereby reducing the incidence of mild obstructive sleep apnea.

##### **Technological Characteristics**

The pillow consists of a custom-fitted high resiliency urethane foundation, an overlying "memory foam" supporting the head and neck, a stretch terry-cloth cover, and removable foam inserts. The PillowPositive is comprised of a thin central area for supine sleeping and two thicker, sloped side panels with earwells for side sleeping.

##### **Performance Data**

LifeSleep sponsored a pilot study and a pivotal study to assess the PillowPositive's use in the reduction of symptoms associated with mild obstructive sleep apnea. The pilot study showed a statistically significant reduction in the Respiratory Disturbance Index (*i.e.*, apneas and hypopneas) among subject with mild obstructive sleep apnea. The pivotal study indicated that the PillowPositive produces a statistically significant reduction in subject's Respiratory Disturbance Index, a key indicator of sleep apnea, in subjects with mild sleep apnea.

##### **Summary of the Basis for the Finding of Substantial Equivalence**

The LifeSleep PillowPositive for the reduction of the symptoms associated with mild obstructive sleep apnea has the same intended use as the Dr. Jonathan A. Parker's PM Positioner, and Adjustable PM Positioner. The Pillow Positive for the reduction of symptoms associated with mild sleep apnea has similar principles or operation as the PM Positioner, the Adjustable PM Positioner, and the A-Just Right Pillow. The PillowPositive for the reduction of symptoms associated with mild obstructive sleep apnea has the same technological characteristics as the legally marketed PillowPositive for snoring and very similar technological features as Ortho-Rest Company's A-Just Right Pillow. The minor differences between the intended use and

the technological characteristics of LifeSleep's PillowPositive for the reduction of symptoms associated with mild obstructive sleep apnea and its predicate devices present no new issues of safety and effectiveness. Moreover, the clinical data demonstrate that the device reduces the symptoms (apneas/hypopneas) associated with mild obstructive sleep apnea. Therefore, the LifeSleep PillowPositive for the reduction of symptoms associated with mild obstructive sleep apnea is substantially equivalent to its legally marketed predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JUN 10 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

LifeSleep System, Inc. Pillow Positive  
C/o Mr. Howard M Holstein  
Hogan & Hartson L.L.P.  
555 Thirteenth Street, N.W.  
Washington, DC 20004-1109

Re: K990871  
Trade Name: PillowPositive Cervical Pillow  
Regulatory Class: unclassified  
Product Code: 77 MYB  
Dated: March 16, 1999  
Received: March 16, 1999

Dear Mr. Holstein:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "A. Ralph Rosenthal". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

A. Ralph Rosenthal, M.D.

Director

Division of Ophthalmic Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

510(k) Number (if known): \_\_\_\_\_

Device Name: LifeSleep Systems, Inc. PillowPositive Cervical Pillow


Indications for Use:

**PillowPositive Cervical Pillow ("PillowPositive") is indicated for the reduction of symptoms (apneas and hypopneas) associated with mild obstructive sleep apnea.**

✓

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Ophthalmic Devices

510(k) Number K990871

6/9/99

Prescription Use ✓  
(Per 21 C.F.R. 801.109)

OR

Over-The-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)